SUPPLEMENTARY DATA

Supplementary Table S1. Clinical and biological parameters before and after nivolumab initiation.

	Before nivolumab initiation	**After 21 months**
Weight (kg)	51	46.9
Body Mass Index (kg/m²)	18.1	16.8
Glycemia (mmol/L), NR : 4.4-6.4	5.5	24.9
HbA1c (% / mmol/mol), NR<6.5 / 47.5	6.0 / 42.1	11.4 / 101
Total Cholesterol (mmol/L), NR: 3.5-7	7.4	6.3
Triglycerides (mmol/L), NR: 0.4-1.7	0.79	6.4
HDL-C (mmol/L), NR >1.3	2.8	0.95
LDL-C (mmol/L), NR: 1.9-4.1	4.1	3.5
ASAT (Ui/L), NR : 0-34	25	158
ALAT (Ui/L), NR : 0-55	11	91
GGT (Ui/L), NR : 9-36	14	46
Insulin (mUi/L)	5.9	40
C-Peptide (nmol/L), NR: 0.37-1.47	0.62	2.3
HOMA-IR, NR<3	1.44	44.3
TyG Index (NR<4.49)	4.36	6.19
Leptin (ng/mL)	3.62	<1
Adiponectin (ug/mL), NR: 0.86-21.4	19.5	0.84

HbA1c= Hemoglobin A1C, HDL-C= High Density Lipoprotein cholesterol, LDL-C= Low density lipoprotein cholesterol, ASAT= Aspartate aminotransferase, ALAT= Alanine aminotransferase, GGT= Gamma-Glutamyl-Transpeptidase, HOMA-IR= Homeostasis Model Assessment of Insulin Resistance, TyG = Triglyceride-glucose index (Log [fasting triglycerides (mg/dl) × fasting glucose (mg/dl)/2])
Nivolumab was discontinuated after 18 months of therapy.

SUPPLEMENTARY DATA

Supplementary Figure S1. Contrast-enhanced abdominal CT at the level of liver segment VIII, with measurement of liver, spleen and muscle radiodensity, showing the appearance of a severe liver steatosis under nivolumab therapy.



	4 months before nivolumab initiation	18 months after nivolumab initiation	7 months after nivolumab discontinuation and 3 months after initiation of insulin therapy
Mean liver radiodensity (UH)	125.3	40.3	93.9
Mean muscle radiodensity (UH)	63.9	61	70.4
Mean spleen radiodensity (UH)	139.3	108.2	136
Liver-to- Muscle Ratio (LMR)	1.96	0.66	1.33